Format

Send to

Choose Destination
See comment in PubMed Commons below
J Clin Pathol. 2013 Mar;66(3):256-9. doi: 10.1136/jclinpath-2012-201020. Epub 2012 Oct 19.

CD24: a potential new marker in differentiating malignant mesothelioma from pulmonary adenocarcinoma.

Author information

1
Department of Experimental Medicine, Imperial Center for Translational and Experimental Medicine, Imperial College London, London, UK.

Abstract

BACKGROUND:

The differential diagnosis between malignant mesothelioma (MM) and metastatic lung adenocarcinoma (MLA) often relies on immunohistochemical studies, with no individual immunomarker holding satisfactory discrimination ability.

METHODS:

We investigated the diagnostic accuracy of CD24 immunoreactivity on 134 patients including 69 cases of MM and 65 MLA.

RESULTS:

The expression of CD24 favoured MLA, with 57/65 cases showing positive cytoplasmic staining compared with 9/69 MM (p<0.001), whose immunopositivity pattern was prevalently membranous (7/9 cases).

CONCLUSIONS:

CD24 positivity can accurately discriminate MM from MLA. Prospective studies are warranted to clarify whether CD24 could integrate with other immunomarkers to facilitate the diagnosis of mesothelial malignancies.

PMID:
23087328
DOI:
10.1136/jclinpath-2012-201020
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center